Market closed
ALX Oncology/$ALXO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ALX Oncology
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Ticker
$ALXO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
80
Website
ALX Oncology Metrics
BasicAdvanced
$48M
-
-$2.58
1.01
-
Price and volume
Market cap
$48M
Beta
1.01
52-week high
$17.83
52-week low
$0.89
Average daily volume
1.2M
Financial strength
Current ratio
7.262
Quick ratio
6.954
Long term debt to equity
12.877
Total debt to equity
14.943
Interest coverage (TTM)
-82.40%
Management effectiveness
Return on assets (TTM)
-45.62%
Return on equity (TTM)
-88.91%
Valuation
Price to book
0.42
Price to tangible book (TTM)
0.42
Price to free cash flow (TTM)
-0.381
Growth
Earnings per share change (TTM)
-30.91%
3-year earnings per share growth (CAGR)
7.67%
What the Analysts think about ALX Oncology
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for ALX Oncology stock.
ALX Oncology Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ALX Oncology Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ALX Oncology News
AllArticlesVideos
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewsWire·5 days ago
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event
GlobeNewsWire·7 days ago
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for ALX Oncology stock?
ALX Oncology (ALXO) has a market cap of $48M as of March 12, 2025.
What is the P/E ratio for ALX Oncology stock?
The price to earnings (P/E) ratio for ALX Oncology (ALXO) stock is 0 as of March 12, 2025.
Does ALX Oncology stock pay dividends?
No, ALX Oncology (ALXO) stock does not pay dividends to its shareholders as of March 12, 2025.
When is the next ALX Oncology dividend payment date?
ALX Oncology (ALXO) stock does not pay dividends to its shareholders.
What is the beta indicator for ALX Oncology?
ALX Oncology (ALXO) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.